Fujifilm Diosynth Biotechnologies has opened new and advanced 10,000ft² cell culture process development laboratories in Wilton Centre, Teesside, UK.

The company is a contract development and manufacturing organisation (CDMO) that focuses on the development and production of recombinant biopharmaceuticals and advanced therapies.

The laboratories have been built using a JPY1bn ($9m) investment, which is part of the JPY14bn ($130m) expansion plan confirmed by Fujifilm in April this year.

Brampton Lord David Gifford Leathes Prior said that the new facility is expected to create new sustainable, high-tech job opportunities in the region.

Fujifilm Diosynth Biotechnologies chief scientific officer Andy Topping said: “These laboratories are designed to incorporate the latest high-throughput technologies, including fully automated high throughput bioreactors and chromatography systems.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The Saturn process development laboratories are a huge differentiator in the cell culture and monoclonal antibody process development space."

The new facilities have been designed specifically to support the Saturn mAb Platform cell culture process development activities.

The Saturn mAb Platform will provide the laboratories with rapid access to process development and manufacturing capacity.

Fujifilm Diosynth Biotechnologies UK sites chief operating officer Paul Found said: “The Saturn process development laboratories are a huge differentiator in the cell culture and monoclonal antibody process development space.

“By dedicating these facilities and bringing new technologies we will be effectively supporting our customers in the rapid delivery of monoclonal antibody therapies to patients all over the world. This is part of our commitment as partners for life in the advancement of medicines.”

Image: Wilton Centre in Teesside after the completion of outfitting of its 10,000ft² cell culture process development laboratories. Photo: courtesy of Fujifilm / Businesswire.